<?xml version='1.0' encoding='utf-8'?>
<document id="26696140"><sentence text="Investigation of Fluorescein Derivatives as Substrates of Organic Anion Transporting Polypeptide (OATP) 1B1 To Develop Sensitive Fluorescence-Based OATP1B1 Inhibition Assays."><entity charOffset="17-28" id="DDI-PubMed.26696140.s1.e0" text="Fluorescein" /></sentence><sentence text="Organic anion transporting polypeptide (OATP) 1B1 plays an important role in the hepatic uptake of various drugs" /><sentence text=" Because OATP1B1 is a site of drug-drug interactions (DDIs), evaluating the inhibitory potential of drug candidates on OATP1B1 is required during drug development" /><sentence text=" For establishing a highly sensitive, high-throughput fluorescence-based OATP1B1 inhibition assay system, the present study focused on fluorescein (FL) and its derivatives and evaluated their uptake via OATP1B1 as well as OATP1B3 and OATP2B1 using the transporter-expressing human embryonic kidney 293 cells" /><sentence text=" We identified 2',7'-dichlorofluorescein (DCF), 4',5'-dibromofluorescein (DBF), and Oregon green (OG) as good OATP1B1 substrates with Km values of 5"><entity charOffset="15-40" id="DDI-PubMed.26696140.s5.e0" text="2',7'-dichlorofluorescein" /></sentence><sentence text="29, 4" /><sentence text="16, and 54" /><sentence text="1 μM and Vmax values of 87" /><sentence text="9, 48" /><sentence text="1, and 187 pmol/min/mg protein, respectively" /><sentence text=" In addition to FL, fluo-3, and 8-fluorescein-cAMP, OG, and DBF were identified as OATP1B3 substrates" /><sentence text=" FL, OG, DCF, and DBF were identified as OATP2B1 substrates"><entity charOffset="5-7" id="DDI-PubMed.26696140.s12.e0" text="OG" /><entity charOffset="9-12" id="DDI-PubMed.26696140.s12.e1" text="DCF" /><pair ddi="false" e1="DDI-PubMed.26696140.s12.e0" e2="DDI-PubMed.26696140.s12.e0" /><pair ddi="false" e1="DDI-PubMed.26696140.s12.e0" e2="DDI-PubMed.26696140.s12.e1" /></sentence><sentence text=" Among the FL derivatives, DCF displayed the highest OATP1B1-mediated uptake"><entity charOffset="11-13" id="DDI-PubMed.26696140.s13.e0" text="FL" /><entity charOffset="27-28" id="DDI-PubMed.26696140.s13.e1" text="DCF" /><pair ddi="false" e1="DDI-PubMed.26696140.s13.e0" e2="DDI-PubMed.26696140.s13.e0" /><pair ddi="false" e1="DDI-PubMed.26696140.s13.e0" e2="DDI-PubMed.26696140.s13.e1" /></sentence><sentence text=" The Ki values of 14 compounds on OATP1B1 determined with DCF as a probe exhibited good agreement with those obtained using [(3)H]estradiol-17β-glucuronide (E2G) as a substrate, whereas [(3)H]estrone-3-sulfate and [(3)H]sulfobromophthalein yielded higher Ki values for all inhibitors than DCF"><entity charOffset="58-61" id="DDI-PubMed.26696140.s14.e0" text="DCF" /><entity charOffset="124-155" id="DDI-PubMed.26696140.s14.e1" text="[(3)H]estradiol-17β-glucuronide" /><entity charOffset="157-160" id="DDI-PubMed.26696140.s14.e2" text="E2G" /><entity charOffset="186-209" id="DDI-PubMed.26696140.s14.e3" text="[(3)H]estrone-3-sulfate" /><entity charOffset="214-239" id="DDI-PubMed.26696140.s14.e4" text="[(3)H]sulfobromophthalein" /><entity charOffset="289-313" id="DDI-PubMed.26696140.s14.e5" text="DCF" /><pair ddi="false" e1="DDI-PubMed.26696140.s14.e0" e2="DDI-PubMed.26696140.s14.e0" /><pair ddi="false" e1="DDI-PubMed.26696140.s14.e0" e2="DDI-PubMed.26696140.s14.e1" /><pair ddi="false" e1="DDI-PubMed.26696140.s14.e0" e2="DDI-PubMed.26696140.s14.e2" /><pair ddi="false" e1="DDI-PubMed.26696140.s14.e0" e2="DDI-PubMed.26696140.s14.e3" /><pair ddi="false" e1="DDI-PubMed.26696140.s14.e0" e2="DDI-PubMed.26696140.s14.e4" /><pair ddi="false" e1="DDI-PubMed.26696140.s14.e0" e2="DDI-PubMed.26696140.s14.e5" /><pair ddi="false" e1="DDI-PubMed.26696140.s14.e1" e2="DDI-PubMed.26696140.s14.e1" /><pair ddi="false" e1="DDI-PubMed.26696140.s14.e1" e2="DDI-PubMed.26696140.s14.e2" /><pair ddi="false" e1="DDI-PubMed.26696140.s14.e1" e2="DDI-PubMed.26696140.s14.e3" /><pair ddi="false" e1="DDI-PubMed.26696140.s14.e1" e2="DDI-PubMed.26696140.s14.e4" /><pair ddi="false" e1="DDI-PubMed.26696140.s14.e1" e2="DDI-PubMed.26696140.s14.e5" /><pair ddi="false" e1="DDI-PubMed.26696140.s14.e2" e2="DDI-PubMed.26696140.s14.e2" /><pair ddi="false" e1="DDI-PubMed.26696140.s14.e2" e2="DDI-PubMed.26696140.s14.e3" /><pair ddi="false" e1="DDI-PubMed.26696140.s14.e2" e2="DDI-PubMed.26696140.s14.e4" /><pair ddi="false" e1="DDI-PubMed.26696140.s14.e2" e2="DDI-PubMed.26696140.s14.e5" /><pair ddi="false" e1="DDI-PubMed.26696140.s14.e3" e2="DDI-PubMed.26696140.s14.e3" /><pair ddi="false" e1="DDI-PubMed.26696140.s14.e3" e2="DDI-PubMed.26696140.s14.e4" /><pair ddi="false" e1="DDI-PubMed.26696140.s14.e3" e2="DDI-PubMed.26696140.s14.e5" /><pair ddi="false" e1="DDI-PubMed.26696140.s14.e4" e2="DDI-PubMed.26696140.s14.e4" /><pair ddi="false" e1="DDI-PubMed.26696140.s14.e4" e2="DDI-PubMed.26696140.s14.e5" /></sentence><sentence text=" Mutually competitive inhibition observed between DCF and E2G suggested that they share the same binding site on OATP1B1"><entity charOffset="50-52" id="DDI-PubMed.26696140.s15.e0" text="DCF" /><entity charOffset="58-60" id="DDI-PubMed.26696140.s15.e1" text="E2G" /><pair ddi="false" e1="DDI-PubMed.26696140.s15.e0" e2="DDI-PubMed.26696140.s15.e0" /><pair ddi="false" e1="DDI-PubMed.26696140.s15.e0" e2="DDI-PubMed.26696140.s15.e1" /></sentence><sentence text=" Therefore, DCF as well as E2G can be used as sensitive probes for in vitro OATP1B1 inhibition assays, which will help mitigate the risk of false-negative DDI predictions potentially caused by substrate-dependent Ki variations"><entity charOffset="12-14" id="DDI-PubMed.26696140.s16.e0" text="DCF" /><entity charOffset="27-29" id="DDI-PubMed.26696140.s16.e1" text="E2G" /><pair ddi="false" e1="DDI-PubMed.26696140.s16.e0" e2="DDI-PubMed.26696140.s16.e0" /><pair ddi="false" e1="DDI-PubMed.26696140.s16.e0" e2="DDI-PubMed.26696140.s16.e1" /></sentence><sentence text="" /></document>